The company announced that it has received encouraging feedback from the United States Food and Drug Administration following a recent Type C meeting, marking a significant moment in its clinical development journey.

The Auckland-based regenerative medicine company has finished its Symphony randomised controlled trial, a multi-centre study focused on treating diabetic foot ulcers, one of the most persistent and costly complications of diabetes.

Genetic Signatures has unveiled an organisational overhaul aimed at sharpening its commercial focus while significantly reducing costs, marking a pivotal moment in the company’s next phase of growth.

AusBiotech has reinforced its role as Australia’s life sciences peak body through direct engagement in national discussions shaping the future of research, development, and innovation

AusBiotech has reinforced its role as Australia’s life sciences peak body through a strong national presence at Science Meets Parliament 2026 as a first-time partner, elevating sector priorities and strengthening engagement with policymakers.

Liberty Specialty Markets has introduced a new insurance solution aimed at supporting the rapidly evolving life sciences sector across the Asia Pacific, positioning itself to address a long-standing gap in specialised coverage for the industry.

Researchers from Monash University, collaborating with Seaport Therapeutics, have unveiled a promising new way to deliver medicines orally by harnessing the body’s natural fat-absorption pathways.

The company said the deal signals a clear move from late-stage clinical development toward building the infrastructure required for a potential commercial launch of its lead diagnostic candidate, 64Cu SAR bisPSMA.

BCAL chief executive Shane Ryan described the rollout as an important milestone, highlighting the company’s collaboration with leading pathology providers to accelerate access.

Melbourne-based Amplia Therapeutics, a company focused on developing targeted cancer therapies, has released updated data from its ongoing ACCENT clinical trial. The findings point to outcomes that stand out in a disease long defined by poor prognosis and limited therapeutic breakthroughs.

Celosia Therapeutics has taken a significant step forward in the fight against amyotrophic lateral sclerosis, announcing that the first patient has been dosed in its Phase 1b clinical trial of CTx1000, an experimental genetic medicine targeting a key driver of the disease.

Radiopharm Theranostics (ASX:RAD) has reported encouraging interim results from its ongoing Phase 2b clinical trial of RAD 101, an experimental imaging agent designed to improve the detection of recurrent brain metastases.

Cyclopharm (ASX:CYC) has taken a significant step forward in its United States expansion, securing a multi-site agreement with the University of Pennsylvania Health System, one of the country’s most respected academic healthcare networks.

Emyria (ASX:EMD) has moved a step closer to establishing its first Empax clinic in Victoria, with patient treatments still expected to begin in the second quarter of 2026 as key operational and clinical milestones are achieved.

Orthocell (ASX:OCC) has reported that its Remplir nerve repair device has been used in 23 surgical procedures on Ukrainian soldiers in combat, marking a significant real-world application of the company’s regenerative medicine technology in a conflict setting.

Driving south along Blackburn Road in Clayton, Melbourne, Professor Robyn Ward, Deputy Vice-Chancellor for Research and Enterprise at Monash University and Chair of the Pharmaceutical Benefits Advisory Committee, sees more than an unremarkable stretch of suburban road.

As early bird registration remains open until 27 March, AusMedtech 2026 is steadily coming into view. For many in the sector, it is not just about the formal presentations but also the in-between moments when conversations unfold, and ideas begin to take shape.